SCHEMBL2815905

SCHEMBL2815905

CN(O)C(=O)c1ccc(Cc2nc(C(N)=O)c(NC(=O)Nc3ccc(C(F)(F)F)cc3)[nH]2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TBXA2R P21731 1/20 0.42
PTGDR Q13258 1/20 0.42
PTGDR2 Q9Y5Y4 1/20 0.42
EPHX2 P34913 5/20 0.40
MCHR1 Q99705 1/20 0.40
MTOR P42345 2/20 0.38
KCNJ6 P48051 1/20 0.38
KCNJ3 P48549 1/20 0.38
TYMP P19971 1/20 0.38
KMT2A Q03164 2/20 0.38
MEN1 O00255 1/20 0.38
MAPT P10636 1/20 0.38
HTT P42858 1/20 0.38
RAB9A P51151 1/20 0.38
HIF1A Q16665 1/20 0.37
EPAS1 Q99814 1/20 0.37
PDE2A O00408 1/20 0.37
LMNA P02545 1/20 0.37
TP53 P04637 1/20 0.37
NAMPT P43490 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17957252 0.92 TBXA2R (0.45) TBXA2RPTGDRPTGDR2EPHX2MCHR1
SCHEMBL2819274 0.89 EPHX2 (0.43) TBXA2RPTGDRPTGDR2EPHX2MCHR1
SCHEMBL2816965 0.88 EPHX2 (0.53) TBXA2RPTGDRPTGDR2EPHX2MTOR
SCHEMBL2813822 0.87 MAPT (0.43) TBXA2RPTGDRPTGDR2EPHX2MCHR1
SCHEMBL2812870 0.87 EPHX2 (0.43) TBXA2RPTGDRPTGDR2EPHX2MCHR1
SCHEMBL2813899 0.86 EPHX2 (0.46) EPHX2MTORTYMPKMT2AMEN1
SCHEMBL2815908 0.85 EPHX2 (0.44) TBXA2RPTGDRPTGDR2EPHX2MCHR1
SCHEMBL17957254 0.85 TBXA2R (0.43) TBXA2RPTGDRPTGDR2EPHX2MCHR1
SCHEMBL2816640 0.85 EPHX2 (0.45) EPHX2MTORTYMPKMT2AMEN1
SCHEMBL2817947 0.84 HIF1A (0.48) TBXA2RPTGDRPTGDR2EPHX2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2193122-B1 IMIDAZOLE DERIVATIVES MERCK PATENT GMBH (DE) 2016-08-03 EP claimed
US-20100249132-A1 IMIDAZOLE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2010-09-30 US claimed
US-20100249132-A1 IMIDAZOLE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2010-09-30 US disclosed
US-20100249132-A1 IMIDAZOLE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2010-09-30 US disclosed
US-20100249132-A1 IMIDAZOLE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2010-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249132-A1 IMIDAZOLE DERIVATIVES SDHA, SDHB, TPD52L2 TBXA2R 871/4885PTGDR 254/4885PTGDR2 372/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.